Current development of virotherapy in breast cancer: a brief review
DOI:
https://doi.org/10.2478/AMB-2024-0084Keywords:
breast cancer, virotherapy, potential therapy, immunotherapy, virusesAbstract
Breast cancer is the cancer with the greatest incidence in the world by 2020. This cancer has a high mortality rate, has the capability of metastasizing, and causes damage to important organs of the human body. Therefore, a lot of studies have been done to find the best therapy to overcome this problem. However, cancer has various special abilities that make it survive and continue to invade its host body, for example, the ability to evade its host immune system by several mechanisms. One of the potential cancer therapies is
virotherapy. Virotherapy is a therapeutic method using viruses to destroy cancer cells. Several mechanisms can be provided by viruses, such as stimulating the host immune system and inducing apoptosis of cancer cells. Especially for breast cancer, there are 4 groups of
viruses based on their genome that have oncolytic capability, such as the dsDNA, dsRNA, + ssRNA, and -ssRNA groups. Currently, there are several therapeutic virotherapy-based modalities for breast cancer that are in clinical trial phases. Each trial has shown positive
results in developing virotherapy for breast cancer.
References
Qadir MI, Ghafoor S. Awareness about Intestinal Cancer in University Student. Nov Approaches Cancer Study 2018;1.
Moiseenko F, Volkov N, Bogdanov A, et al. Resistance mechanisms to drug therapy in breast cancer and other solid tumors: An opinion. F1000Res 2017;6:288. https://doi.org/10.12688/ f1000research.10992.1.
CDC. What is Breast Cancer 2020. https://www.cdc.gov/cancer/breast/basic_info/what-is-breast-cancer.htm (accessed March 5, 2021).
Sun YS, Zhao Z, Yang ZN, et al. Risk factors and preventions of breast cancer. Int J Biol Sci 2017;13:1387–97. https://doi. org/10.7150/ijbs.21635.
Kumar V, Abbas AK, Aster JC, Robbins SL. Robbins basic pathology. 9th ed. Philadelphia, PA : Elsevier/Saunders, ©2013; 2013.
Salamat F, Niakan B, Keshtkar A, Rafiei E, Zendehdel M. Subtypes of benign breast disease as a risk factor of breast cancer: A systematic review and meta analyses. Iran J Med Sci 2018;43:355–64.
Sasmana IGAP, Surudarma IW, Wiryanthini IAD, et al. The role of anthocyanin in obesity. Romanian Society of Diabetes, Nutrition and Metabolic Diseases 2024;31:1–9.
Tsuji W, Plock JA. Breast Cancer Metastasis. Introduction to Cancer Metastasis 2017;320:13–31. https://doi.org/10.1016/ B978-0-12-804003-4.00002-5.
American Cancer Society. Survival Rates for Breast Cancer 2021. https://www.cancer.org/cancer/breast-cancer/understanding-a-breast-cancer-diagnosis/breast-cancer-survival-rates.html (accessed March 6, 2021).
Sasmana IGAP, Wiranata S, Yogananda KC, et al. Clinico-pathological and Prognostic Significance of SRY-Box Transcription Factor 2 ( SOX2 ) Overexpression in Central Nervous System Tumor : A Meta-Analysis. Bali Medical Journal 2023;12:1733–9. https://doi.org/10.15562/bmj.v12i2.4493.
Chakraborty S, Rahman T. The difficulties in cancer treatment. Ecancermedicalscience 2012;6:ed16. https://doi.org/10.3332/
ecancer.2012.ed16.
R. Nahas G, A. Patel S, A. Bliss S, Rameshwar P. Can Breast Cancer Stem Cells Evade the Immune System? Curr Med Chem 2012;19:6036–49. https://doi.org/10.2174/092986712804485863.
Bramante S, Koski A, Liikanen I, et al. Oncolytic virotherapy for treatment of breast cancer, including triple-negative breast cancer. Oncoimmunology 2016;5:1–8. https://doi.org/10.1080 /2162402X.2015.1078057.
Motalleb G. Virotherapy in cancer. Iran J Cancer Prev 2013;6:101–7.
Sagara M, Miyamoto S, Itoh s, et al. Development of New Oncolytic Virotherapy Targeting Breast Cancer Using Cox
sackievirus B3. Anticancer Res 2021;41:81 LP – 89. https:// doi.org/10.21873/anticanres.14753.
Vasan N, Toska E, Scaltriti M. Overview of the relevance of PI3K pathway in HR-positive breast cancer. Ann Oncol 2019;30:x3–11. https://doi.org/10.1093/annonc/mdz281.
Sever R, Brugge JS. Signal Transduction in Cancer. Cold Spring Harb Perspect Med 2015;5. https://doi.org/10.1101/ cshperspect.a006098.
Kontomanolis EN, Koutras A, Syllaios A, et al. Role of oncogenes and tumor-suppressor genes in carcinogenesis: A review. Anticancer Res 2020;40:6009–15. https://doi. org/10.21873/anticanres.14622.
Wee P, Wang Z. Epidermal growth factor receptor cell proliferation signaling pathways. Cancers (Basel) 2017;9:1–45. https://doi.org/10.3390/cancers9050052.
Feng Y, Spezia M, Huang S, et al. Breast cancer development and progression: Risk factors, cancer stem cells, signaling pathways, genomics, and molecular pathogenesis. Genes Dis 2018;5:77–106. https://doi.org/10.1016/j.gendis.2018.05.001.
Roskoski R. The ErbB/HER family of protein-tyrosine kinases and cancer. Pharmacol Res 2014;79:34–74. https://doi.
org/10.1016/j.phrs.2013.11.002.
Arteaga CL, Engelman JA. ERBB receptors: From oncogene discovery to basic science to mechanism-based cancer therapeutics. Cancer Cell 2014;25:282–303. https://doi. org/10.1016/j.ccr.2014.02.025.
Liu Q, Kulak M V, Borcherding N, et al. A novel HER2 gene body enhancer contributes to HER2 expression. Oncogene 2018;37:687–94. https://doi.org/10.1038/onc.2017.382.
Kumar V, Abbas A, Aster J, Perkins JA. Robbins & Cotran Pathologic Basis of Disease. 9th ed. Philadelphia, PA : Elsevier/Saunders, ©2015; 2015.
Johnston CJC, Smyth DJ, Dresser DW, Maizels RM. TGF-β in tolerance, development and regulation of immunity. Cell Immunol
;299:14–22. https://doi.org/10.1016/j.cellimm.2015.10.006.
Chen L, Flies DB. Molecular mechanisms of T cell co-stimulation and co-inhibition. Nat Rev Immunol 2013;13:227–42.
https://doi.org/10.1038/nri3405.
Russell SJ, Peng K-W, John CB. ONCOLYTIC VIROTHERAPY. HHS Public Access 2014;30:658–670.
Fournier P, Schirrmacher V. Oncolytic newcastle disease virus as cutting edge between tumor and host. Biology (Basel) 2013;2:936–75. https://doi.org/10.3390/biology2030936.
Goetz C, Dobrikova E, Shveygert M, et al. Oncolytic poliovirus against malignant glioma. Future Virol 2011;6:1045–58. https://doi.org/10.2217/fvl.11.76.
Kemp V, van den Wollenberg DJM, Camps MGM, et al. Arming oncolytic reovirus with GM-CSF gene to enhance immunity. Cancer Gene Ther 2019;26:268–81. https://doi. org/10.1038/s41417-018-0063-9.
Chaurasiya S, Fong Y, Warner SG. Optimizing oncolytic viral design to enhance antitumor efficacy: Progress and challenges. Cancers (Basel) 2020;12:1–20. https://doi.org/10.3390/ cancers12061699.
Russell L, Whye K, Russell SJ, Diaz RM. Oncolytic Viruses : Priming Time for Cancer Immunotherapy. BioDrugs 2019;33:485–501. https://doi.org/10.1007/s40259-019-00367-0.
Manuscript A. NIH Public Access 2014; 14:1014–22. https:// doi.org/10.1038/ni.2703.Innate.
Vloten JP Van, Workenhe ST, Sarah K, et al. Critical Interactions between Immunogenic Cancer Cell Death, Oncolytic Viruses, and the Immune System Define the Rational Design of Combination Immunotherapies 2021. https://doi.org/10.4049/ jimmunol.1701021.
Melchjorsen J, Gymnasium E. Learning from the Messengers: Innate Sensing of Viruses and Cytokine Regulation of Immunity — Clues for Treatments and Vaccines 2013:470527. https://doi.org/10.3390/v5020470.
Hemminki O, Diaconu I, Cerullo V, et al. Ad3-hTERT-E1A , a Fully Serotype 3 Oncolytic Adenovirus, in Patients With Chemotherapy Refractory Cancer 2012;20:1821–30. https://doi. org/10.1038/mt.2012.115.
Martini V, Avanzo FD, Maggiora PM, et al. Oncolytic virotherapy : new weapon for breast cancer treatment 2020:1–19.
Kasuya H. Genomic Signature of the Natural Oncolytic Herpes Simplex virus HF10 and its Therapeutic Role in Preclinical and Clinical Trials 2017;7:1–12. https://doi.org/10.3389/ fonc.2017.00149.
Rehman H, Silk AW, Kane MP, Kaufman HL. Into the clinic: Talimogene laherparepvec (T-VEC), a first-in-class intratumoral oncolytic viral therapy. J Immunother Cancer 2016:1–8. https://doi.org/10.1186/s40425-016-0158-5.
Nanni P, Gatta V, Menotti L, et al. Preclinical Therapy of Disseminated HER-2+ Ovarian and Breast Carcinomas with a HER-2-Retargeted Oncolytic Herpesvirus. PLoS Pathog 2013;9:1–10. https://doi.org/10.1371/journal.ppat.1003155.
Walker JD, Sehgal I, Kousoulas KG. Oncolytic Herpes Simplex Virus 1 Encoding 15-Prostaglandin Dehydrogenase Mitigates Immune Suppression and Reduces Ectopic Primary and Metastatic Breast Cancer in Mice. J Virol 2011;85:7363-71. https://doi.org/10.1128/jvi.00098-11.
Hemminki O, Parviainen S, Juhila J, et al. Immunological data from cancer patients treated with Ad5/3-E2F-Δ24-GMCSF suggests utility for tumor immunotherapy. Oncotarget 2015;6:4467–81. https://doi.org/10.18632/oncotarget.2901.
Bramante S, Koski A, Kipar A, et al. Serotype chimeric oncolytic adenovirus coding for GM-CSF for treatment of sarcoma in rodents and humans. Int J Cancer 2014;135:720–30. https://doi.org/10.1002/ijc.28696.
Bramante S. Oncolytic adenovirus coding for GM-CSF in treatment of cancer. 2015.
Platonov ME, Borovjagin A V., Kaverina N, Xiao T, Kadagidze Z, Lesniak M, et al. KISS1 tumor suppressor restricts angiogenesis of breast cancer brain metastases and sensitizes them to oncolytic virotherapy in vitro. Cancer Lett 2018;417:75–88. https://doi.org/10.1016/j.canlet.2017.12.024.
Papaoiconomou E, Lymperi M, Petraki C, et al. Kiss-1/ GPR54 protein expression in breast cancer. Anticancer Res 2014;34:1401–7.
Zhu W, Wei L, Zhang H, et al. Oncolytic adenovirus armed with IL-24 Inhibits the growth of breast cancer in vitro and in vivo. Journal of Experimental and Clinical Cancer Research 2012; 31. https://doi.org/10.1186/1756-9966-31-51.
O`Bryan SM, Mathis JM. Oncolytic Virotherapy for Breast Cancer Treatment. Curr Gene Ther 2018; 18:192–205.
https://doi.org/10.2174/1566523218666180910163805.
Lee P, Clements D, Helson E, Gujar S. Reovirus in cancer therapy: an evidence-based review. Oncolytic Virother 2014:69. https://doi.org/10.2147/ov.s51321.
Holl EK, Brown MC, Boczkowski D, et al. Recombinant oncolytic poliovirus, PVSRIPO, has potent cytotoxic and innate inflammatory effects, mediating therapy in human breast and prostate cancer xenograft models. Oncotarget 2016; 7:79828–41. https://doi.org/10.18632/oncotarget.12975.
Pol JG, Matthew J, Bridle BW, et al. Development and applications of oncolytic Maraba virus vaccines 2018:117–28.
Deng X, Shen Y, Yi M, et al. Combination of novel oncolytic herpesvirus with paclitaxel as an efficient strategy for breast cancer therapy. J Med Virol 2023;95. https://doi.org/10.1002/ jmv.28768.
Zhang H, Ren Y, Wang F, et al. The long-term effectiveness and mechanism of oncolytic virotherapy combined with anti-PD-L1 antibody in colorectal cancer patient. Cancer Gene Ther 2024. https://doi.org/10.1038/s41417-024-00807-2.
Monge C, Xie C, Myojin Y, et al. Phase I/II study of PexaVec in combination with immune checkpoint inhibition in refractory metastatic colorectal cancer. J Immunother Cancer 2023;11. https://doi.org/10.1136/jitc-2022-005640.
Zhang H, Ren Y, Wang F, et al. The long-term effectiveness and mechanism of oncolytic virotherapy combined with anti-PD-L1 antibody in colorectal cancer patient. Cancer Gene Ther 2024. https://doi.org/10.1038/s41417-024-00807-2.
Bernstein V, Ellard SL, Dent SF, et al. A randomized phase II study of weekly paclitaxel with or without pelareorep in patients with metastatic breast cancer: final analysis of Canadian Cancer Trials Group IND.213. Breast Cancer Res Treat 2018;167:485–93. https://doi.org/10.1007/s10549-017-45384.
Chesney J, Puzanov I, Collichio F, et al. Randomized, Open Label Phase II Study Evaluating the Efficacy and Safety of Talimogene Laherparepvec in Combination With Ipilimumab Versus Ipilimumab Alone in Patients With Advanced, Unresectable Melanoma. J Clin Oncol 2017; 36:1658–67. https:// doi.org/10.1200/JCO.
Ye W, Liu R, Pan C, et al. Multicenter Randomized Phase 2 Clinical Trial of a Recombinant Human Endostatin Adenovirus in Patients with Advanced Head and Neck Carcinoma. Molecular Therapy 2014;22:1221–9. https://doi.org/10.1038/ mt.2014.53.
Kuczynski EA, Vermeulen PB, Pezzella F, et al. Vessel cooption in cancer. Nat Rev Clin Oncol 2019;16:469–93. https:// doi.org/10.1038/s41571-019-0181-9.
Zheng M, Huang J, Tong A, Yang H. Oncolytic Viruses for Cancer Therapy: Barriers and Recent Advances. Mol Ther Oncolytics 2019;15:234–47. https://doi.org/10.1016/j. omto.2019.10.007.
Hagedorn C, Kreppel F. Capsid Engineering of Adenovirus Vectors: Overcoming Early Vector–Host Interactions for Therapy. Hum Gene Ther 2017;28:820–32. https://doi. org/10.1089/hum.2017.139
Downloads
Published
Issue
Section
License
Copyright (c) 2024 I. Sasmana, P. Putri, N. Dewi, I. Supadmanaba, D. Wihandani (Author)
This work is licensed under a Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International License.
You are free to share, copy and redistribute the material in any medium or format under these terms.
Journal Acta Medica Bulgarica 
